Consistently, by dividing patients based on the WHO grade, we found that Grade IV GBM showed significantly a lower NKD1-mRNA level than Grade II or Grade III gliomas (Figure 1(b), P < 0.001). The gene discussed is NKD1; the disease is central nervous system cancer.